ResultsIQ

ResultsIQ › Latest results › Medplus Health Services Limited

Medplus Health Services Limited Q1 FY27 earnings call summary

NSE: MEDPLUS · BSE: 543427

Earnings call of 22 Jul 2026, summarised by AI from the filing.

MedPlus Q1 FY27 revenue ₹18,796 million with 3.5% operating EBITDA margin; capex plans put on hold and 800 net store additions guided for FY27.

Key takeaways

  1. Q1 revenue Consolidated revenue ₹18,796 million; operating EBITDA ₹651 million at 3.5% margin.
  2. Capex pause Board-approved food park and wellness capex put on hold after market and investor feedback.
  3. Margin risk Gross margin down 200 bps sequentially on private label mix, inventory provisions and supplier discounts.

Original filing on BSE

Medplus Health Services Limited Q1 FY27 results

As filed: Revenue ₹1,880 cr (+22% year on year), EBITDA ₹133 cr (+2% year on year), PAT ₹33.2 cr (−21% year on year), EBITDA margin 7.1% (−140 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹1,864 cr (+23% year on year), EBITDA ₹169 cr (+24% year on year), PAT ₹64.0 cr (+25% year on year), EBITDA margin 9.1% (+7 bps). Score 57 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were below it. EBITDA margin was flat year on year. Other income 26% of PBT. Profit rose ₹13.0 cr on a year ago, against ₹17.0 cr the year before. Share price after the results: −1.9% in 30 days (Nifty 500: −2.5%).
  • Q3 FY26: Revenue ₹1,806 cr (+16% year on year), EBITDA ₹159 cr (+20% year on year), PAT ₹57.8 cr (+26% year on year), EBITDA margin 8.8% (+33 bps). Score 43 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was well below it; profit growth was below it. EBITDA margin rose 33 bps year on year. Share price after the results: +3.1% in 28 days (Nifty 500: +0.4%).
  • Q2 FY26: Revenue ₹1,679 cr (+7% year on year), EBITDA ₹150 cr (+21% year on year), PAT ₹56.0 cr (+44% year on year), EBITDA margin 8.9% (+107 bps). Score 30 of 100, Below trend. Revenue and profit growth were below the company's own trend; EBITDA growth was well below it. EBITDA margin rose 107 bps year on year. Share price after the results: +6.0% in 28 days (Nifty 500: +0.9%).
  • Q1 FY26: Revenue ₹1,543 cr (+4% year on year), EBITDA ₹131 cr (+39% year on year), PAT ₹42.0 cr (+200% year on year), EBITDA margin 8.5% (+218 bps). Score 53 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA growth was well above it; profit growth was above it. EBITDA margin rose 218 bps year on year. Other income 28% of PBT. Profit fell 18% from last quarter. Profit rose ₹28.0 cr on a year ago, more than the ₹10.0 cr it added the year before. Share price after the results: −9.0% in 30 days (Nifty 500: +0.2%).
  • Q4 FY25: Revenue ₹1,510 cr (+1% year on year), EBITDA ₹136 cr (+28% year on year), PAT ₹51.0 cr (+50% year on year), EBITDA margin 9.0% (+190 bps). Score 45 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA and profit growth were below it. EBITDA margin rose 190 bps year on year. Other income 26% of PBT. Revenue fell 3% from last quarter. Revenue rose ₹19.0 cr on a year ago, against ₹238 cr the year before. Share price after the results: −4.9% in 30 days (Nifty 500: +3.1%).
  • Q3 FY25: Revenue ₹1,561 cr (+8% year on year), EBITDA ₹132 cr (+43% year on year), PAT ₹46.0 cr (+229% year on year), EBITDA margin 8.5% (+207 bps). Score 76 of 100, Above trend. EBITDA margin rose 207 bps year on year. Not enough history for a trend yet: scored on growth alone.
  • Q2 FY25: Revenue ₹1,576 cr, EBITDA ₹124 cr, PAT ₹39.0 cr, EBITDA margin 7.9%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹1,576 cr). Scored once a year-earlier consolidated quarter exists.

Past price moves after results do not indicate future moves. Not a recommendation.

Medplus Health Services Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.